Aridis Pharmaceuticals, Inc. Los Gatos, CA
Stanford University School of Medicine (former Adjunct Clinical Faculty)
Alan H Cohen, MD
Dr. Alan H. Cohen is a board-certified pediatric pulmonologist, microbiologist, and member of Aridis’ Clinical Advisory Board (2007-on). In addition to his many years of clinical practice, research and teaching, he has dedicated more than half of his professional career to the field of drug discovery, in the Biotech & Pharma Drug Development space, at both small, entrepreneurial pre-IPO start-ups, as well as more well-established public companies worldwide.
His research and drug development career have included roles of increasing responsibility and leadership at companies such as: Matagenomi (where he is currently FT as SVP and CMO), Eidos Therapeutics/BridgeBio, Bayer, Therabron Therapeutics, Eddingpharm, Boehringer Ingelheim, InterMune (acquired by Roche/Genentech), MAP Pharma (acquired by Allergan), Jazz Pharma and Medimmune (acquired by AZ).
Dr Cohen is the author of over 100 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise, including Pulmonary Disorders such as idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), premature lung disease, asthma and the field of lung transplantation as well as respiratory infectious diseases – such as RSV, influenza, S. aureus and P. aeruginosa.
Dr. Cohen most recently served as adjunct clinical and teaching faculty at Stanford University School of Medicine – in the Dept. of Pediatric Pulmonology. He has additionally held faculty appointments at a number of prestigious centers of learning and healthcare including the Johns Hopkins School of Medicine, Morehouse School of Medicine, Washington University School of Medicine, as well as the University of Colorado / National Jewish Center for Immunology and Respiratory Diseases – where he completed his residency and fellowship in pediatrics and pulmonary medicine, respectively.